{
    "clinical_study": {
        "@rank": "95948", 
        "arm_group": {
            "arm_group_label": "Quetiapine XR", 
            "arm_group_type": "Experimental", 
            "description": "Patients had schizophrenia and fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability (N=61). They will receive the intervention of administration of quetiapine XR."
        }, 
        "brief_summary": {
            "textblock": "Purpose To evaluate the efficacy and safety of once-daily quetiapine extended release (XR)\n      in patients with schizophrenia switched from other antipsychotics which were suboptimal due\n      to insufficient efficacy or insufficient tolerability.\n\n      Methods:\n\n      This was a 12-week, open-label study conducted in the Chinese population in Taiwan.\n      Quetiapine XR was administrated at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after\n      day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within\n      400-800 mg per day, depending on the clinical response and tolerability of the patients."
        }, 
        "brief_title": "The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The participants who were aged from 20 to 65 years and met the diagnosis of\n             schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders,\n             fourth edition, text revision (DSM-IV-TR) were eligible for the recruitment to the\n             clinical trial.\n\n          -  They also fulfilled the criteria including having a score of 4 (moderate) or greater\n             on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive\n             Symptom Subscale and needed to switch from previous antipsychotics due to\n             insufficient efficacy or insufficient tolerability.\n\n        Exclusion Criteria:\n\n          -  Any DSM-IV-TR Axis I disorder other than schizophrenia, except comorbid\n             obsessive-compulsive disorder, anxiety disorder, eating disorders or impulse control\n             disorders if they had been stable and had not been primary focus of treatment over\n             the previous 6 months\n\n          -  An imminent risk of suicide or a danger to self or others\n\n          -  Pregnancy or lactation\n\n          -  Intolerance or lack of response to quetiapine IR\n\n          -  Use of cytochrome P450 3A4 inhibitors or inducers in the 14 days preceding enrolment\n\n          -  Administration of a depot antipsychotic injection within one dosing interval before\n             recruitment\n\n          -  Unstable or inadequately treated medical illness as judged by the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142556", 
            "org_study_id": "D1443L00046"
        }, 
        "intervention": {
            "arm_group_label": "Quetiapine XR", 
            "description": "The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.", 
            "intervention_name": "Administration of quetiapine XR", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antipsychotic Agents", 
                "Quetiapine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "114"
                }, 
                "name": "Tri-Service General Hospital, National Defense Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Efficacy and Safety of Once-daily Quetiapine Extended Release in Patients With Schizophrenia Switched From Other Antipsychotics", 
        "other_outcome": [
            {
                "description": "The patient's vital signs and body weight will be measured at screening and every visit schedule (week 1, 2, 4, 8, 12). An electrocardiogram and laboratory measurements including hematology and glycosylated hemoglobin (HbA1c) will be performed at enrolment and week 12.", 
                "measure": "Other Safety Assessments-the measure is a composite for metabolic disturbance", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Another efficacy endpoint was the difference from baseline to the end of study in Clinical Global Impression-Severity (CGI-S) score in the participants.", 
                "measure": "Another efficacy assessment-CGI-S", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Other scales used to evaluate the extrapyramidal symptoms (EPS) associated with the previous antipsychotics or quetiapine XR were Abnormal Involuntary Movement Scale (AIMS), Barnes-Akathisia Rating scale (BARS) and Simpson-Angus Scale (SAS). The use of anticholinergic medications during the treatment period will also be recorded.", 
                "measure": "other safety assessments-the measure is a composite for EPS", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Tri-Service General Hospital, National Defense Medical Center", 
            "last_name": "Chin-Bin Yeh, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Taiwan : Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The variable of the primary endpoint was the change from baseline to Week 12 in PANSS total and subscale score.", 
            "measure": "Efficacy Assessments", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142556"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tri-Service General Hospital", 
            "investigator_full_name": "Chin-Bin Yeh", 
            "investigator_title": "Chief, Associate Professor, Department of Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The occurrence and severity of adverse events (AEs) will be recorded throughout the study to assess the tolerability of quetiapine XR, including AEs spontaneously reported by the patients or observed by the staff.", 
            "measure": "Safety Assessments", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "source": "Tri-Service General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Tri-Service General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}